Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

NCT05766371 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Castrate Resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Prostate Cancer
Prostate Carcinoma

Interventions

DRUG: Pembrolizumab
DRUG: 177Lu-PSMA-617

Sponsor

University of California, San Francisco

Collaborators

[object Object]
[object Object]